SG11201608006QA - Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor - Google Patents
Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens thereforInfo
- Publication number
- SG11201608006QA SG11201608006QA SG11201608006QA SG11201608006QA SG11201608006QA SG 11201608006Q A SG11201608006Q A SG 11201608006QA SG 11201608006Q A SG11201608006Q A SG 11201608006QA SG 11201608006Q A SG11201608006Q A SG 11201608006QA SG 11201608006Q A SG11201608006Q A SG 11201608006QA
- Authority
- SG
- Singapore
- Prior art keywords
- bleeding
- prevention
- treatment
- dosing regimens
- life extended
- Prior art date
Links
- 208000032843 Hemorrhage Diseases 0.000 title 1
- 208000034158 bleeding Diseases 0.000 title 1
- 230000000740 bleeding effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978218P | 2014-04-11 | 2014-04-11 | |
| EP14167612 | 2014-05-09 | ||
| EP14168389 | 2014-05-15 | ||
| PCT/AU2015/050137 WO2015154139A1 (en) | 2014-04-11 | 2015-03-30 | Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608006QA true SG11201608006QA (en) | 2016-10-28 |
Family
ID=54287020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608006QA SG11201608006QA (en) | 2014-04-11 | 2015-03-30 | Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170042981A1 (https=) |
| EP (1) | EP3129408A4 (https=) |
| JP (1) | JP2017513831A (https=) |
| KR (1) | KR20160143820A (https=) |
| CN (1) | CN106164097A (https=) |
| AU (1) | AU2015245941A1 (https=) |
| BR (1) | BR112016023158A2 (https=) |
| CA (1) | CA2944174A1 (https=) |
| MX (1) | MX2016013281A (https=) |
| RU (1) | RU2016144159A (https=) |
| SG (1) | SG11201608006QA (https=) |
| WO (1) | WO2015154139A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018294517B2 (en) * | 2017-06-29 | 2024-09-26 | CSL Behring Lengnau AG | 21-day dosing regimen for fusion proteins comprising factor IX and human albumin for prophylactic treatment of hemophilia and methods thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9458444B2 (en) * | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| PT2101821E (pt) * | 2006-12-15 | 2014-10-03 | Baxter Int | Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo |
| WO2011020866A2 (en) * | 2009-08-20 | 2011-02-24 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| KR20120002129A (ko) * | 2010-06-30 | 2012-01-05 | 한미홀딩스 주식회사 | 면역글로불린 단편을 이용한 제７인자（Ｆａｃｔｏｒ Ⅶａ）약물 결합체 |
-
2015
- 2015-03-30 BR BR112016023158A patent/BR112016023158A2/pt not_active Application Discontinuation
- 2015-03-30 RU RU2016144159A patent/RU2016144159A/ru not_active Application Discontinuation
- 2015-03-30 SG SG11201608006QA patent/SG11201608006QA/en unknown
- 2015-03-30 CN CN201580018873.8A patent/CN106164097A/zh not_active Withdrawn
- 2015-03-30 CA CA2944174A patent/CA2944174A1/en not_active Abandoned
- 2015-03-30 US US15/302,597 patent/US20170042981A1/en not_active Abandoned
- 2015-03-30 KR KR1020167031632A patent/KR20160143820A/ko not_active Withdrawn
- 2015-03-30 WO PCT/AU2015/050137 patent/WO2015154139A1/en not_active Ceased
- 2015-03-30 EP EP15775929.1A patent/EP3129408A4/en not_active Withdrawn
- 2015-03-30 MX MX2016013281A patent/MX2016013281A/es unknown
- 2015-03-30 JP JP2016561735A patent/JP2017513831A/ja active Pending
- 2015-03-30 AU AU2015245941A patent/AU2015245941A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN106164097A (zh) | 2016-11-23 |
| JP2017513831A (ja) | 2017-06-01 |
| CA2944174A1 (en) | 2015-10-15 |
| AU2015245941A1 (en) | 2016-11-17 |
| MX2016013281A (es) | 2017-01-18 |
| BR112016023158A2 (pt) | 2017-10-17 |
| RU2016144159A3 (https=) | 2018-11-26 |
| US20170042981A1 (en) | 2017-02-16 |
| EP3129408A1 (en) | 2017-02-15 |
| WO2015154139A1 (en) | 2015-10-15 |
| EP3129408A4 (en) | 2018-04-25 |
| RU2016144159A (ru) | 2018-05-11 |
| KR20160143820A (ko) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260275B (en) | Identifying the source of sideloading software | |
| SG10201800851XA (en) | Cytotoxicity-inducing therapeutic agent | |
| SI3197472T1 (sl) | Rekombinantni proteini brez PHE za uporabo pri zdravljenju fenilketonurije | |
| SG11201606108RA (en) | Heteroarly amides as inhibitors of protein aggregation | |
| IL249455A0 (en) | Complexes of mineral-amino acids with active substances | |
| IL259101A (en) | Melflufen dosage regimens for cancer | |
| IL251870A0 (en) | Dosing regimens of buprenorphine | |
| IL264804B (en) | Regimens and methods of treating multiple sclerosis using ofatumumab | |
| SG11201507254VA (en) | Novel dosing regimens of celgosivir for the treatment of dengue | |
| IL265762A (en) | Dosing regimen of avolumab for cancer treatment | |
| IL277377B (en) | Prohemostatic proteins for the treatment of bleeding | |
| GB201406172D0 (en) | Therapy and pharmaceutical composition | |
| SG11201710686PA (en) | Hair treatment agent | |
| GB201418809D0 (en) | Therapeutic agents and uses thereof | |
| IL252191A0 (en) | Compositions and methods for modulating at2r activity | |
| HUE055980T2 (hu) | Javított aktivitású exoglükazánok variánsai és alkalmazásaik | |
| SG11201608006QA (en) | Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor | |
| GB201516836D0 (en) | Dosing regimen of combination | |
| GB201417248D0 (en) | Compostion and methods of treatment | |
| IL248101A0 (en) | Factor fviia protein with an extended half-life for the treatment of bleeding and its regimens | |
| HK1228926A1 (en) | Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor | |
| SG10201912141YA (en) | Novel dosing regimens of celgosivir for the prevention of dengue | |
| IL248506A0 (en) | Dosage regimens of nitisinone for the treatment of alkeptonuria | |
| SI3326626T1 (sl) | Sredstvo za zdravljenje dermatomikoze, ki obsega trikalijev citrat | |
| SG11201801083UA (en) | Tumor therapeutic agent |